Stevanato Group SpA logo

Stevanato Group SpA(STVN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$15.65
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for STVN

11/20/2026: STVN (1-star) is currently NOT-A-BUY. Pass it for now.

Stevanato Group SpA is a global life sciences company that provides drug containment, delivery, and diagnostic solutions alongside specialized manufacturing equipment. The company operates with a major market position supported by proprietary technologies, long-standing biopharmaceutical customer relationships, and an integrated business model. Its primary investment story centers on secular growth in biologic drugs, GLP-1 therapies, and self-administered medical devices. However, the company faces risks related to capital expenditure intensity, customer concentration, and execution hurdles during facility expansions. It suits growth-oriented investors looking for exposure to pharmaceutical supply chains, though monitoring capacity ramp-ups and valuation multiples remains essential.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company benefits from structural tailwinds in biologics, GLP-1 demand, and self-administration trends driving long-term volume expansion.
Momentum investorMixed fitMomentum fit is conditional on a positive Upturn signal as the stock experiences periodic sector-driven volatility and valuation adjustments.
Value investorMixed fitValuation multiples fluctuate based on broader healthcare sentiment, making entry point timing crucial for value-oriented investors.
Dividend investorWeak fitStevanato Group prioritizes capital reinvestment and capacity expansion over high-yield dividend payouts.
Low-risk investorMixed fitWhile supported by a sticky, mission-critical customer base, cross-border operational exposure and capital intensity introduce moderate risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock can experience sharp price swings driven by macro sentiment changes and quarterly earnings delivery.
Valuation riskMediumGrowth expectations are partially priced in, leaving less room for execution missteps or delayed facility ramps.
Competition risk (glass containment and delivery systems)MediumRival packaging and medical device suppliers constantly vie for pharmaceutical contracts and technological superiority.
Business qualityStrongMission-critical, sticky customer relationships and high regulatory entry barriers support a durable underlying franchise quality.
Dividend incomeLowIncome-focused investors will find minimal yield as cash is retained for business reinvestment.
Execution riskMedium / highSuccessfully executing major greenfield plant expansions on time and within budget is critical for sustaining growth targets.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.27B USD
Price to earnings Ratio 26.53
1Y Target Price 19.46
Price to earnings Ratio 26.53
1Y Target Price 19.46
Volume (30-day avg) 1.0M shares
Beta 0.8
52 Weeks Range 12.05 - 23.92
Updated Date 11/21/2026
52 Weeks Range 12.05 - 23.92
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.59

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Medical Instruments & Supplies

BUY participation
50.0%
Active BUY / eligible
1 / 2
30-Day BUY Count Change
+1

Eligible universe: 2 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -51.12%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
STVN receives a 3-star rating, supported by solid company fundamentals, solid quantitative characteristics, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
STVN has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+14.0%) and solid profitability (net margin 11.8%) are partially offset by soft cash generation (FCF margin 1.9%), moderate revenue growth (+3.2%), modest insider ownership of 1.87%.

Financial Health Rating

★★★★★
STVN's financial health is supported by solid cash strength, including free-cash-flow generation (1.9% of revenue). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is STVN's strongest growth driver at +113.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+14.0%, solid) is also solid, while revenue growth (+3.2%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 100.4% and approximately 98.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.87% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Conestoga Capital Advisors, LLC 2.57%
Neuberger Berman Group LLC 2.06%
TimesSquare Capital Management, LLC 1.19%
Van Berkom and Associates Inc 1.05%
Artisan Partners Limited Partnership 0.95%

Unit Economics (Per $1K Revenue)

★★★★★
STVN generates approximately $290 of gross profit, $161 of operating income, and $19 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins explain the 2-star rating, with weak cash conversion and soft capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 26.07%

Quantitative Style Profile

★★★★★
STVN has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical and Diagnostic SolutionsRevenues derived from selling drug containment systems (vials, syringes, cartridges) and proprietary drug delivery devices like auto-injectors.This is the primary revenue engine, benefiting from recurring drug consumption and biologic prescription volumes.
Engineering SegmentSales of specialized glass converting machines, visual inspection equipment, and assembly automation lines to pharmaceutical manufacturers.Provides cyclical capital equipment revenue that complements its consumable packaging footprint.
Geographic DistributionGlobal sales spanning Europe, the Middle East, Africa, North America, South America, and Asia-Pacific.International diversification helps insulate the company from regional economic slowdowns.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-03
When Before Market
Estimate 0.17
Actual 0.18

Profitability

Profit Margin 11.25%
Operating Margin (TTM) 17.95%

Management Effectiveness

Return on Assets (TTM) 5.51%
Return on Equity (TTM) 9.26%

Valuation

Trailing PE 26.53
Forward PE 24.88
Enterprise Value 4.74B
Price to Sales(TTM) 3.42
Enterprise Value 4.74B
Price to Sales(TTM) 3.42
Enterprise Value to Revenue 3.46
Enterprise Value to EBITDA 14.06
Shares Outstanding 49.83M
Shares Floating 49.00M
Shares Outstanding 49.83M
Shares Floating 49.00M
Percent Insiders 1.87
Percent Institutions 100.42

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.